Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.9492 -0.0558 (-5.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024 ↗
RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From RenovoRx , Inc.
Via Business Wire
News headline image
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
News headline image
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023 ↗
RNXT stock results show that RenovoRx met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning! 
Via InvestorPlace
News headline image
RenovoRx Announces $11.1 Million at Market Private Placement
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
Via Get News
Topics Intellectual Property
News headline image
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Issues New Patent Application Adding to Strong IP Portfolio of 9 Patents Issued and 9 Pending; Phase 3 Clinical Trials for Cancer Treatments in Collaboration with Imugene: RenovoRx (NASDAQ: RNXT) $RNXT
Via Viz Release
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.